Plain-English translation of NCT06427447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether patients who have had pancreatic cancer surgery benefit from receiving both chemotherapy (using gemcitabine and capecitabine) and radiation therapy together, or from chemotherapy alone. The trial will compare these two treatment approaches in people whose cancer has certain high-risk features, such as spread to lymph nodes or incomplete removal of the tumor during surgery.
Even after surgery, most people with pancreatic cancer experience cancer returning or spreading. While chemotherapy is standard treatment after surgery, doctors are uncertain whether adding radiation therapy helps certain patients live longer. This trial aims to answer that question with solid evidence.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy as an injection over several weeks (6 cycles, each lasting 3 weeks). If randomly assigned to the chemoradiotherapy group, you will then receive radiation therapy for several weeks, with chemotherapy given at the same time. If assigned to chemotherapy alone, your treatment ends after the 6 cycles. You will have regular blood tests and imaging scans to monitor your health and check for any signs of cancer returning.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China